ImmunityBio, Inc. (26CA)
XMUN 
Summary
26CA Chart
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up
IBRX wins conditional EU approval for its Anktiva+BCG bladder cancer combo, sending shares soaring 41.9% and expanding its global footprint to 33 countries.
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last?
ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer, with robust commercial traction—FY25 revenue reached ~$113 million, up 700% YoY. Key pipeline catalysts include upcoming trial readouts in bladder cancer and glioblastoma; positive data could drive further upside, but valuation is highly sensitive to setbacks.
ImmunityBio, Inc. (26CA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has ImmunityBio, Inc. ever had a stock split?
ImmunityBio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard Gerald Adcock CEO | XMUN Exchange | US45256X1037 ISIN |
| US Country | 671 Employees | - Last Dividend | - Last Split | 28 Jul 2015 IPO Date |
Overview
ImmunityBio, Inc. is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of next-generation immuno- and cellular therapies. These therapies target cancer and infectious diseases, with operations spanning the United States and Europe. The company leverages its expertise to offer cutting-edge immunotherapy and cell therapy platforms aimed at enhancing patient outcomes. Through strategic collaboration agreements and licensing arrangements with various entities, including the National Cancer Institute and Amyris, Inc., ImmunityBio is working towards advancing its promising pipeline of therapies. The company is headquartered in San Diego, California, reflecting its strong presence in one of the world’s leading biotechnology hubs.
Products and Services
- Anktiva (N-803)
- Immunotherapy and Cell Therapy Platforms
- Collaborations and Licensing Agreements
An IL-15 superagonist antibody-cytokine fusion protein, Anktiva (N-803), represents ImmunityBio’s lead biologic commercial product candidate. It is designed for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without Ta or T1 disease. This highlights ImmunityBio’s focus on addressing hard-to-treat cancers through innovative biologic treatments.
ImmunityBio’s platforms encompass a variety of immunotherapy and cell therapy solutions aimed at fighting against cancer and infectious diseases. This includes antibody cytokine fusion proteins like N-803, sophisticated vaccine delivery technologies, and natural killer cell therapies. Through these platforms, the company is able to target a broad spectrum of liquid and solid tumors, as well as other severe diseases, demonstrating its versatility and innovation in the biotechnological field.
The company’s collaborative efforts and licensing agreements with institutions such as the National Cancer Institute, LadRx Corporation, GlobeImmune, Inc., and others play a critical role in bolstering its research and development activities. These partnerships facilitate the harnessing of external expertise and technologies, thereby enriching ImmunityBio’s product pipeline and accelerating the pace of innovation in treatments for cancer and infectious diseases.
